A pilot trial by investigators from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the drug Foralumab, an anti-CD3 monoclonal antibody.
Reducing the methylation of a key messenger RNA can promote migration of macrophages into the brain and ameliorate symptoms of Alzheimer’s disease in a mouse model, according to a new study publishing March 7th in the open access journal PLOS Biology by Rui Zhang of Air Force Medical University in Xian, Shaanxi, China. The results illuminate one pathway for entrance of peripheral immune cells into the brain, and may provide a new target for treatment of Alzheimer’s disease.
A United States Food and Drug Administration mandate to limit the dosage of acetaminophen in pills that combine acetaminophen and opioid medications is significantly associated with subsequent reductions in serious liver injury.
New research has shown that the blood vessels that feed aggressive brain tumours have receptors that could allow a new type of drug-containing nanoparticle to be used to starve the tumours of the energy they use to grow and spread, and also cause other disruptions to their adapted existence, even killing themselves.
A shot of a liver-produced hormone called FGF21 sobered up mice that had passed out from alcohol, allowing them to regain consciousness and coordination much faster than those that didn’t receive this treatment, UT Southwestern researchers report in a new study. The findings, published in Cell Metabolism, could lead to effective treatments for acute alcohol intoxication, which is responsible for about 1 million emergency room visits in the U.S. each year.
A novel compound that has the potential to starve the bacteria that causes tuberculosis – the world’s leading infectious killer after SARS-CoV2 – is entering human clinical trials.
A global team of researchers has created an algorithmic tool that can identify existing drugs in order to combat future pandemics. The work, reported in the Cell Press journal Heliyon, offers the possibility of responding more quickly to public-health crises.
Denovo Biopharma LLC ("Denovo"), a pioneer in applying precision medicine to the development of innovative therapies, set up a gene registry web portal and invites people who suffer from treatment-resistant depression (TRD) to visit www.iMatchDepression.com to help identify whether they or someone they know may be eligible to participate in a biomarker-guided global Phase 2b clinical trial (the "ENLIGHTEN" study).
Treatment with the drug memantine was associated with significant improvements compared to a placebo for patients with trichotillomania and excoriation disorders.
High-dose anticoagulation can reduce deaths by 30 percent and intubations by 25 percent in hospitalized COVID-19 patients who are not critically ill when compared to the standard treatment, which is low-dose anticoagulation.
Value in Health, the official journal of ISPOR, announced the publication of a series of articles describing important new research related to drug pricing globally. The articles were published in the March 2023 issue of the journal.
Psychiatry researchers at Washington University School of Medicine in St. Louis, led a multicenter study that found, in older adults with treatment-resistant depression, that augmenting an antidepressant drug with aripiprazole helped a significant number of patients.
Pain afflicts at least 1.5 billion people worldwide, and despite the availability of various painkilling drugs, not all forms of pain are treatable.
A combination treatment that targets the immune system helps treat aggressive prostate cancers that don’t respond to conventional therapies.
The Foundation for Anesthesia Education and Research (FAER) announced it has established an endowed National Academy of Medicine (NAM) fellowship to provide early-career anesthesiology scholars with the opportunity to experience and participate in committee, workshop, and roundtable activities of NAM and the National Academy of Sciences (NAS).
Mount Sinai Health System and Memorial Sloan Kettering Cancer Center researchers have developed a new drug delivery approach that uses nanoparticles to enable more effective and targeted delivery of anti-cancer drugs to treat brain tumors in children.
The discovery of a strain of bacteria shown to reduce inflammation in the intestine caused by irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) could bring relief to millions of sufferers after being turned into an innovative natural food supplement by University of Bristol biotech spin-out Ferryx.
The ERP Biomarker Qualification Consortium announced today the successful completion of a pharma industry-sponsored study to measure the electrophysiologic effects of ketamine on healthy brain function.
The Endocrine Society commends Eli Lilly and Company for taking steps to reduce insulin prices and make insulin affordable for more people with diabetes.
A team of researchers from institutions across the United States, including Moffitt Cancer Center, launched a phase 2 clinical trial evaluating a new treatment option for this patient population. Their results, published in The New England Journal of Medicine, show that treating resectable stage 3 and 4 melanoma patients with the immunotherapy drug pembrolizumab both before and after surgery greatly improves outcomes when compared to pembrolizumab given only after surgery.
Patients with high-risk melanoma who received the immunotherapy drug pembrolizumab both before and after surgery to remove cancerous tissue had a significantly lower risk of their cancer recurring than similar patients who received the drug only after surgery.
Cardiovascular medicine, hematology and pulmonary medicine may soon have the first-ever therapies to correct poor tissue oxygenation, a key driver of disease in millions, including peripheral artery disease, sickle cell disease, heart failure, stroke, emphysema and many others. The breakthrough follows a landmark discovery from investigators at Harrington Discovery Institute at University Hospitals (UH) and Case Western Reserve University School of Medicine. The research team showed that a modified version of hemoglobin, termed S-nitrosohemoglobin, senses areas with insufficient oxygen, and then restores blood flow for oxygenation. The study recently published in PNAS.
20240326113011.png&width=400&height=400){kind=logo}
A new technique that targets and breaks apart certain proteins — rather than just interfering with them — may offer a pathway toward treatment of Alzheimer's disease. Researchers reporting in ACS Central Science have designed a compound that breaks down a protein closely associated with the disease.
For the past few decades, Dr. Iwao Ojima has been working in his Stony Brook University Department of Chemistry Laboratory to develop next-generation anti-cancer agents. One of these agents – a second-generation taxane conjugate (called NE-DHA-SBT-1214) – has shown great promise against solid tumors – particularly against colorectal cancer.
The word ‘evolution’ may bring to mind dusty dinosaur bones, but it impacts our health every day.
Scientists at St. Jude Children’s Research Hospital showed an effective method to avoid activating a major cellular detoxification receptor to overcome drug resistance and toxicity.
Heart disease is the leading cause of death worldwide, killing someone in the United States every 34 seconds, according to the Centers for Disease Control and Prevention. A new study by investigators from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, conducted the first population-based study on patients’ nonacceptance of statin therapy recommendations.
National Organization for Rare Disorders (NORD®) Founder and past President Abbey S. Meyers, PhD, former U.S. Rep. Jaime Herrera Beutler of Washington State, New York Yankees centerfielder Bernie Williams, and pioneer clinical geneticist, Dr.Ada Hamosh, headline a group of rare disease champions who will be honored for their outstanding contributions to the rare disease community at NORD's 2023 Rare Impact Awards (RIA).
The TCT Geoffrey O. Hartzler Master Operator Award will be presented to William L. Lombardi, MD during Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT will take place October 23-26, 2023, in San Francisco at the Moscone Center. The award is given each year to a physician who has advanced the field of interventional cardiovascular medicine through technical excellence and leadership.
Emad Ibrahim, M.D., director of the Male Fertility Research Program at The Miami Project to Cure Paralysis and the clinical andrology lab at the Desai Sethi Urology Institute at the University of Miami Miller School of Medicine, has been awarded a $3.25 million grant by the Department of Defense for a four-year study on the use of an oral medication to treat an infertility issue that affects most men with spinal cord injury.
Black people are receiving medications for dementia less often than white people, according to a preliminary study released today, February 26, 2023, that will be presented at the American Academy of Neurology’s 75th Annual Meeting being held in person in Boston and live online from April 22-27, 2023.
A recent University of Kentucky Markey Cancer Center study suggests a new radiopharmaceutical compound may be a viable treatment option for patients with advanced cervical cancer.
A more mystical and insightful psychedelic drug experience may be linked to an enduring reduction in anxiety and depression symptoms, according to a new study.
People who regularly use laxatives, a common treatment for constipation, may have more than a 50% increased risk of developing dementia than people who do not use laxatives, according to a study published in the February 22, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology. Researchers also found people who used only osmotic laxatives, a type of laxative that attracts water to the colon to soften stool, had an even greater risk. Other types of laxatives are bulk-forming, stool-softening, and stimulating. The study does not prove that laxatives cause dementia. It only shows an association.
Researchers from Oregon Health & Science University and institutions across the country have identified a pill used to treat a common skin disease as an “incredibly promising” treatment for alcohol use disorder.
Below are some of the latest articles that have been added to the Chemistry news channel on Newswise.
Leqembi, Recientemente Aprobado por la FDA, Muestra un Beneficio Potencial para los Pacientes con Enfermedad en Etapa Temprana, pero la Disponibilidad Llevará tiempo, Comenta Experta de Cedars-Sinai
For men undergoing surgery to repair scarring in the urethra (urethroplasty), a new approach to pain management can reduce the need for strong opioid drugs without compromising pain control, reports a study in Urology Practice®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
Researchers at UC Santa Cruz working to develop novel RNA-based medicines are teaming up with a new group of collaborators—players of the online game Eterna. The
Researchers from the University of Washington (UW), Kenya Medical Research Institute (KEMRI), and Hennepin Healthcare Research Institute (HHRI) announced results at CROI from a clinical trial demonstrating that doxycycline taken after sex does not prevent bacterial sexually transmitted infections (STIs) – chlamydia or gonorrhea – among cisgender women.
A vaginal ring containing the antiretroviral drug dapivirine posed no safety concerns when used in the third trimester of pregnancy, according to results to date from the first study of the dapivirine ring during pregnancy and one of only a few studies of an HIV prevention product in pregnant cisgender women.
A University of Maryland School of Medicine researcher and his colleagues at the University of North Carolina Chapel Hill have unveiled the structure of DREADDs (Designer Receptors Activated by Designer Drugs) that will pave the way for creating the next generation of these tools. This step ultimately will bring them closer to an elusive goal — understanding the underpinnings of brain disorders and develop new treatments.
Brexanolone, an IV infusion comprised of a derivative of progesterone, was approved by the U.S. Food and Drug Administration for the treatment of PPD in 2019. The fast-acting medication significantly reduces depression symptoms and provides effects for up to 90 days. However, exactly how the drug provides these therapeutic effects has remained a mystery – until now.
Scientists at the Paul Scherrer Institute PSI have used the Swiss X-ray free-electron laser SwissFEL and the Swiss Light Source SLS to make a film that could give a decisive boost to developing a new type of drug.
Location, location, location is the key for psychedelic drugs that could treat mental illness by rapidly rebuilding connections between nerve cells.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
